@article{9229f3cfc6994f11ac8103c3b0c79e83,
title = "Breast cancer, version 3.2020",
abstract = "Several new systemic therapy options have become available for patients with metastatic breast cancer, which have led to improvements in survival. In addition to patient and clinical factors, the treatment selection primarily depends on the tumor biology (hormone-receptor status and HER2-status). The NCCN Guidelines specific to the workup and treatment of patients with recurrent/stage IV breast cancer are discussed in this article.",
author = "Gradishar, {William J.} and Anderson, {Benjamin O.} and Jame Abraham and Rebecca Aft and Doreen Agnese and Allison, {Kimberly H.} and Blair, {Sarah L.} and Burstein, {Harold J.} and Chau Dang and Elias, {Anthony D.} and Giordano, {Sharon H.} and Goetz, {Matthew P.} and Goldstein, {Lori J.} and Isakoff, {Steven J.} and Jairam Krishnamurthy and Janice Lyons and Marcom, {P. Kelly} and Jennifer Matro and Mayer, {Ingrid A.} and Moran, {Meena S.} and Joanne Mortimer and O{\textquoteright}Regan, {Ruth M.} and Patel, {Sameer A.} and Pierce, {Lori J.} and Rugo, {Hope S.} and Amy Sitapati and Smith, {Karen Lisa} and Smith, {Mary Lou} and Hatem Soliman and Stringer-Reasor, {Erica M.} and Telli, {Melinda L.} and Ward, {John H.} and Young, {Jessica S.} and Burns, {Jennifer L.} and Rashmi Kumar",
note = "Publisher Copyright: {\textcopyright} National Comprehensive Cancer Network, Inc. 2020. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.",
year = "2020",
month = apr,
doi = "10.6004/jnccn.2020.0016",
language = "English (US)",
volume = "18",
pages = "452--478",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "4",
}